SI
Sofinnova Investments Portfolio holdings
AUM
$1.47B
This Quarter Return
+1.73%
1 Year Return
+17.43%
3 Year Return
+337.79%
5 Year Return
+424.38%
10 Year Return
–
AUM
$1.59B
AUM Growth
+$1.59B
(-6.3%)
Cap. Flow
+$23.5M
Cap. Flow
% of AUM
1.48%
Top 10 Holdings %
Top 10 Hldgs %
51.2%
Holding
86
New
16
Increased
31
Reduced
15
Closed
11
Top Buys
| 1 |
Edwards Lifesciences
EW
|
$66.9M |
| 2 |
Stryker
SYK
|
$65.7M |
| 3 |
RAPP
Rapport Therapeutics
RAPP
|
$45.4M |
| 4 |
Align Technology
ALGN
|
$29.7M |
| 5 |
Axsome Therapeutics
AXSM
|
$25M |
Top Sells
| 1 |
Merck
MRK
|
$85.9M |
| 2 |
Incyte
INCY
|
$75.6M |
| 3 |
argenx
ARGX
|
$58.8M |
| 4 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$45.5M |
| 5 |
Insulet
PODD
|
$32.1M |
Sector Composition
| 1 | Healthcare | 99.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Roivant Sciences
ROIV
$8.6B
| $19.7M | 1.03% |
1,868,412
+866,708
| +87% | +$9.16M |
|
27
Establishment Labs
ESTA
$1.11B
| $19.5M | 1.01% |
429,244
+288,082
| +204% | +$13.1M |
|
|
INZY
28
DELISTED
Inozyme Pharma
INZY
| $19.1M | 0.99% |
4,280,308
| – | – |
|
29
Revolution Medicines
RVMD
$7.43B
| $17.7M | 0.92% |
+455,099
| New | +$17.7M |
|
30
Kura Oncology
KURA
$732M
| $17M | 0.88% |
825,243
+323,303
| +64% | +$6.66M |
|
31
Insmed
INSM
$30.3B
| $15.3M | 0.79% |
+227,747
| New | +$15.3M |
|
32
Boston Scientific
BSX
$159B
| $13.2M | 0.68% |
171,080
-182,771
| -52% | -$14.1M |
|
33
Madrigal Pharmaceuticals
MDGL
$9.7B
| $12.4M | 0.65% |
44,417
+25,388
| +133% | +$7.11M |
|
|
34
Insulet
PODD
$24.2B
| $12.3M | 0.64% |
60,967
-159,236
| -72% | -$32.1M |
|
35
Pharvaris
PHVS
$1.41B
| $11.3M | 0.59% |
601,534
+16,862
| +3% | +$317K |
|
|
AXNX
36
DELISTED
Axonics, Inc. Common Stock
AXNX
| $10.1M | 0.53% |
150,490
+1,105
| +0.7% | +$74.3K |
|
37
Immatics
IMTX
$662M
| $9.26M | 0.48% |
796,704
-1,366,942
| -63% | -$15.9M |
|
38
Cabaletta Bio
CABA
$144M
| $9.13M | 0.47% |
1,220,400
+790,654
| +184% | +$5.91M |
|
39
PepGen
PEPG
$39M
| $8.96M | 0.47% |
561,128
+57,504
| +11% | +$918K |
|
40
Edgewise Therapeutics
EWTX
$1.54B
| $8.57M | 0.45% |
+475,691
| New | +$8.57M |
|
41
Immunome
IMNM
$892M
| $7.93M | 0.41% |
655,680
+61,284
| +10% | +$742K |
|
42
Exact Sciences
EXAS
$9.33B
| $7.68M | 0.4% |
181,828
-47,653
| -21% | -$2.01M |
|
|
NARI
43
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $7.5M | 0.39% |
155,838
+145,622
| +1,425% | +$7.01M |
|
44
DexCom
DXCM
$30.9B
| $6.97M | 0.36% |
+61,494
| New | +$6.97M |
|
45
Inhibrx
INBX
$403M
| $6.57M | 0.34% |
+463,315
| New | +$6.57M |
|
46
Achieve Life Sciences
ACHV
$146M
| $6.53M | 0.34% |
1,388,372
-129,858
| -9% | -$610K |
|
47
Waters Corp
WAT
$17.3B
| $6.33M | 0.33% |
+21,804
| New | +$6.33M |
|
|
JBIO
48
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $6.24M | 0.32% |
3,758,686
| – | – |
|
49
4D Molecular Therapeutics
FDMT
$302M
| $5.69M | 0.3% |
271,155
+72,969
| +37% | +$1.53M |
|
|
MRNS
50
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $4.86M | 0.25% |
4,151,576
+2,750,523
| +196% | +$3.22M |
|